➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
Mallinckrodt
Merck
AstraZeneca
Medtronic

Last Updated: March 2, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR HYDROCODONE BITARTRATE AND ACETAMINOPHEN

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Hydrocodone Bitartrate And Acetaminophen

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00236535 A Study of the Efficacy and Safety of Tramadol HCl/Acetaminophen, Hydrocodone Bitartrate/Acetaminophen and Placebo in Patients With Pain From an Ankle Sprain With a Partial Torn Ligament Completed PriCara, Unit of Ortho-McNeil, Inc. Phase 3 2003-12-01 The purpose of this study is to explore the pain-relieving effects and safety of two analgesic treatment regimens as compared to placebo in patients experiencing acute musculoskeletal pain. Patients who are experiencing at least moderate acute musculoskeletal pain from an ankle sprain severe enough to require prescription pain relief medication will be randomized to receive either tramadol HCl/acetaminophen, hydrocodone bitartrate/acetaminophen or placebo.
NCT00236535 A Study of the Efficacy and Safety of Tramadol HCl/Acetaminophen, Hydrocodone Bitartrate/Acetaminophen and Placebo in Patients With Pain From an Ankle Sprain With a Partial Torn Ligament Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Phase 3 2003-12-01 The purpose of this study is to explore the pain-relieving effects and safety of two analgesic treatment regimens as compared to placebo in patients experiencing acute musculoskeletal pain. Patients who are experiencing at least moderate acute musculoskeletal pain from an ankle sprain severe enough to require prescription pain relief medication will be randomized to receive either tramadol HCl/acetaminophen, hydrocodone bitartrate/acetaminophen or placebo.
NCT01456520 Pharmacokinetics and Bioequivalence of Vycavert (10 mg Hydrocodone Bitartrate/325 mg Acetaminophen) Compared to the Reference Drug Norco Completed Pfizer Phase 1 2011-10-01 This study aims to determine whether the hydrocodone and acetaminophen exposures following oral dosing of Vycavert are comparable to those following oral dosing of Norco.
NCT01596673 A Study to Assess the Abuse Potential of Hydrocodone Extended-Release Tablet in Recreational Opioid Users Completed Cephalon Phase 1 2012-03-01 The purpose of this study is to assess the relative abuse potential of the hydrocodone bitartrate extended-release tablet compared to immediate-release hydrocodone bitartrate.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Hydrocodone Bitartrate And Acetaminophen

Condition Name

Condition Name for Hydrocodone Bitartrate And Acetaminophen
Intervention Trials
Opioid-Related Disorders 3
Pain, Postoperative 2
Pain, Acute 2
Pain 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Hydrocodone Bitartrate And Acetaminophen
Intervention Trials
Opioid-Related Disorders 3
Pain, Postoperative 2
Acute Pain 2
Substance-Related Disorders 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Hydrocodone Bitartrate And Acetaminophen

Trials by Country

Trials by Country for Hydrocodone Bitartrate And Acetaminophen
Location Trials
United States 10
Canada 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Hydrocodone Bitartrate And Acetaminophen
Location Trials
Utah 3
Kansas 2
Texas 1
Maryland 1
California 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Hydrocodone Bitartrate And Acetaminophen

Clinical Trial Phase

Clinical Trial Phase for Hydrocodone Bitartrate And Acetaminophen
Clinical Trial Phase Trials
Phase 3 2
Phase 2 1
Phase 1 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Hydrocodone Bitartrate And Acetaminophen
Clinical Trial Phase Trials
Completed 5
Withdrawn 2
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Hydrocodone Bitartrate And Acetaminophen

Sponsor Name

Sponsor Name for Hydrocodone Bitartrate And Acetaminophen
Sponsor Trials
Grünenthal GmbH 2
Pfizer 1
Sun Pharma Advanced Research Company Limited 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Hydrocodone Bitartrate And Acetaminophen
Sponsor Trials
Industry 9
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
Johnson and Johnson
Colorcon
Mallinckrodt
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.